Open AccessSubcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer
Author(s) -
Christian Jackisch,
Daniil Stroyakovskiy,
Xavier Pivot,
Jin Seok Ahn,
Bohuslav Melichar,
ShinCheh Chen,
Christoph Meyenberg,
N. Al-Sakaff,
Dominik Heinzmann,
Roberto Hegg
Publication year - 2019
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2019.0339
Subject(s) - medicine , trastuzumab , epirubicin , breast cancer , docetaxel , hazard ratio , adverse effect , clinical endpoint , oncology , surgery , chemotherapy , clinical trial , cancer , confidence interval
ClinicalTrials.gov identifier: NCT00950300.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom